Business Parks & Science Centres

 
 
 

Advertisement

Picture Berlin Partner HealthCapital Bionnale 2019 Germany May 600x94px
Financing › Details

IEP GmbH–Cambrex: investment, 201003 acquisition to be renamed Cambrex IEP GmbH

 

Period Period 2010-03-22
Organisations Money taker IEP GmbH
  Today Cambrex IEP GmbH
  Group Cambrex (Group)
  Money source Cambrex Corporation (NYSE: CBM)
  Group Cambrex (Group)
Products Product industrial enzyme
  Product 2 biocatalyst
     

Cambrex Corporation. (3/22/2010). "Press Release: Cambrex Acquires IEP GmbH". East Rutherford, NJ.

Cambrex Corporation (NYSE: CBM) announced it has acquired IEP GmbH ("IEP"), a privately held company that is a leader in the field of industrial biocatalysis. IEP is located in Wiesbaden, Germany and offers cost effective customized biocatalytic process development and sales of enzymes to the pharmaceutical industry, with the ability to utilize its tool box of over 100 proprietary biocatalytic enzymes. IEP "bioreduction" technologies have been successfully used in numerous commercialized processes.

"In combination with our existing chiral chemistry business, the acquisition of IEP will result in Cambrex being able to offer a broad biocatalysis platform to the pharmaceutical industry. We are very excited about the future growth of this business, as IEP has demonstrated the introduction of a "green" biocatalytic step in chemical synthesis that can provide significant benefits resulting in the cost efficient, commercial scale production of enantiomerically pure chemical products and intermediates. IEP has assembled, under the leadership of Dr. Antje Gupta, a strong group of highly skilled scientists and built a successful business based on its proprietary technology and intellectual property. We are looking forward to working with the IEP team to expand their business development efforts through the existing Cambrex channels to market," commented Steven Klosk, President & CEO of Cambrex Corporation.

The business will be renamed Cambrex IEP and will remain in Wiesbaden, Germany. For more information on IEP, please visit http://www.biocatalysis.com/.

About Cambrex

Cambrex provides products and services to accelerate the development and commercialization of small molecule active pharmaceutical ingredients ("APIs"), advanced intermediates and other products for branded and generic pharmaceuticals. The Company currently employs approximately 850 people worldwide. For more information, please visit http://www.cambrex.com/.

Contact: Stephanie LaFiura
Investor Relations Associate
201-804-3037
stephanie.lafiura@cambrex.com

   
Record changed: 2017-04-02

Advertisement

Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 600x60px

More documents for Cambrex (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture Berlin Partner HealthCapital Bionnale 2019 Germany May 600x94px




» top